Centers for Disease Control and Prevention. Pneumococcal disease: prevention 2022. [Accessed August 14, 2023]. Available from: https://www.cdc.gov/pneumococcal/surveillance.html.

Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1997;46(Rr-8):1–24.

Google Scholar 

Centers for Disease Control and Prevention. Pneumococcal disease: surveillance and reporting 2020. Available from: https://www.cdc.gov/pneumococcal/surveillance.html. Accessed Oct 5, 2022.

Gierke R, editor. Current epidemiology of pediatric pneumococcal disease, United States. Meeting of the Advisory Committee on Immunization Practices; 2023; Atlanta: Centers for Disease Control and Prevention.

Nuorti JP, Whitney CG. Prevention of pneumococcal disease among infants and children—use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine—recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59(Rr-11):1–18.

PubMed  Google Scholar 

Pfizer. Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine), suspension for intramuscular injection, prescribing information. 2021.

Cohen R, Levy C, Ouldali N, Goldrey M, Bechet S, Bonacorsi S, et al. Invasive disease potential of pneumococcal serotypes in children after PCV13 implementation. Clin Infect Dis. 2021;72(8):1453–6.

Article  PubMed  Google Scholar 

Tomczyk S, Lynfield R, Schaffner W, Reingold A, Miller L, Petit S, et al. Prevention of antibiotic-nonsusceptible invasive pneumococcal disease with the 13-valent pneumococcal conjugate vaccine. Clin Infect Dis. 2016;62(9):1119–25.

Article  CAS  PubMed  Google Scholar 

Harboe ZB, Thomsen RW, Riis A, Valentiner-Branth P, Christensen JJ, Lambertsen L, et al. Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Med. 2009;6(5): e1000081.

Article  PubMed  PubMed Central  Google Scholar 

Oligbu G, Collins S, Sheppard CL, Fry NK, Slack M, Borrow R, et al. Childhood deaths attributable to invasive pneumococcal disease in England and Wales, 2006–2014. Clin Infect Dis. 2017;65(2):308–14.

Article  PubMed  Google Scholar 

Cui YA, Patel H, O’Neil WM, Li S, Saddier P. Pneumococcal serotype distribution: a snapshot of recent data in pediatric and adult populations around the world. Hum Vaccin Immunother. 2017;13(6):1–13.

Article  PubMed  Google Scholar 

Balsells E, Guillot L, Nair H, Kyaw MH. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: a systematic review and meta-analysis. PLoS ONE. 2017;12(5): e0177113.

Article  PubMed  PubMed Central  Google Scholar 

Hausdorff WP, Hanage WP. Interim results of an ecological experiment—conjugate vaccination against the pneumococcus and serotype replacement. Hum Vaccin Immunother. 2016;12(2):358–74.

Article  PubMed  PubMed Central  Google Scholar 

Kobayashi M, editor. Evidence to recommendations framework and policy options: use of 20-valent pneumococcal conjugate vaccine in US children. Meeting of the Advisory Committee on Immunization Practices; 2023; Atlanta, GA.

US Census Bureau. Annual estimates of the resident population by single year of age and sex for the United States: April 1, 2020 to July 1, 2021 (NC-EST2021-SYASEXN): U.S. Census Bureau, Population Division; 2022. Accessed Mar 23, 2023.

Pelton SI, Weycker D, Farkouh RA, Strutton DR, Shea KM, Edelsberg J. Risk of pneumococcal disease in children with chronic medical conditions in the era of pneumococcal conjugate vaccine. Clin Infect Dis. 2014;59(5):615–23.

Article  PubMed  Google Scholar 

Centers for Disease Control and Prevention. Active bacterial core surveillance report, emerging infections program network, Streptococcus pneumoniae, 2019 2019. Available from: www.cdc.gov/abcs/downloads/SPN_Surveillance_Report_2019.pdf. Accessed Nov 17, 2022.

Stoecker C, editor. Economic assessment of PCV15 & PCV20. Advisory Committee on Immunization Practices Meeting; 2021; Atlanta, GA.

Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, et al. Community-acquired pneumonia requiring hospitalization among US adults. N Engl J Med. 2015;373(5):415–27.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ramirez JA, Wiemken TL, Peyrani P, Arnold FW, Kelley R, Mattingly WA, et al. Adults hospitalized with pneumonia in the United States: incidence, epidemiology, and mortality. Clin Infect Dis. 2017;65(11):1806–12.

Article  PubMed  Google Scholar 

Tong S, Amand C, Kieffer A, Kyaw MH. Trends in healthcare utilization and costs associated with pneumonia in the United States during 2008–2014. BMC Health Serv Res. 2018;18(1):715.

Article  PubMed  PubMed Central  Google Scholar 

Tong S, Amand C, Kieffer A, Kyaw MH. Trends in healthcare utilization and costs associated with acute otitis media in the United States during 2008–2014. BMC Health Serv Res. 2018;18(1):318.

Article  PubMed  PubMed Central  Google Scholar 

Lapidot R, Averin A, Weycker D, Huang L, Vietri J, Mohs AGA, et al. Disparities by age, comorbidity profile, and insurance type in the burden of invasive pneumococcal disease and respiratory syndromes among children in the United States. Unpublished.

Centers for Disease Control and Prevention. Active bacterial core surveillance (ABCs) report emerging infections program network Streptococcus pneumoniae, 2018 2018. Available from: https://www.cdc.gov/abcs/reports-findings/survreports/spneu18.pdf. Accessed Nov 17, 2022.

Centers for Disease Control and Prevention. Active bacterial core surveillance (ABCs) report emerging infections program network Streptococcus pneumoniae, 2017 2017. Available from: https://www.cdc.gov/abcs/reports-findings/survreports/spneu17.pdf. Accessed Nov 17, 2022.

Kobayashi M, Farrar JL, Gierke R, Leidner AJ, Campos-Outcalt D, Morgan RL, et al. Use of 15-valent pneumococcal conjugate vaccine among US children: updated recommendations of the advisory committee on immunization practices—United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(37):1174–81.

Article  PubMed  PubMed Central  Google Scholar 

Averin A, Shaff M, Weycker D, Lonshteyn A, Sato R, Pelton SI. Mortality and readmission in the year following hospitalization for pneumonia among US adults. Respir Med. 2021;185: 106476.

Article  PubMed  Google Scholar 

US Census Bureau. National demographic analysis tables: 2020. 2021. Available from: https://www.census.gov/data/tables/2020/demo/popest/2020-demographic-analysis-tables.html. Accessed Nov 17, 2022.

Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Holtzman C, Harrison LH, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case–control study. Lancet Respir Med. 2016;4(5):399–406.

Article  CAS  PubMed  Google Scholar 

Fiore AE, Levine OS, Elliott JA, Facklam RR, Butler JC. Effectiveness of pneumococcal polysaccharide vaccine for preschool-age children with chronic disease. Emerg Infect Dis. 1999;5(6):828–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J. 2000;19(3):187–95.

Article  CAS  PubMed  Google Scholar 

Black SB, Shinefield HR, Ling S, Hansen J, Fireman B, Spring D, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J. 2002;21(9):810–5.

Article  PubMed  Google Scholar 

Hansen J, Black S, Shinefield H, Cherian T, Benson J, Fireman B, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs. Pediatr Infect Dis J. 2006;25(9):779–81.

Article  PubMed  Google Scholar 

Boccalini S, Bechini A, Levi M, Tiscione E, Gasparini R, Bonanni P. Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy. Hum Vaccin Immunother. 2013;9(3):699–706.

Article  PubMed  PubMed Central  Google Scholar 

Cho B-H, Stoecker C, Link-Gelles R, Moore MR. Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions. Vaccine. 2013;31(50):6011–21.

Article  PubMed  Google Scholar 

Fry AM, Zell ER, Schuchat A, Butler JC, Whitney CG. Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly. Vaccine. 2002;21(3):303–11.

Article  PubMed  Google Scholar 

Heo JY, Seo YB, Choi WS, Lee J, Noh JY, Jeong HW, et al. Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea. PLoS ONE. 2017;12(5): e0177342.

Article  PubMed  PubMed Central  Google Scholar 

Hoshi S-L, Kondo M, Okubo I. Economic evaluation of immunisation programme of 23-valent pneumococcal polysaccharide vaccine and the inclusion of 13-valent pneumococcal conjugate vaccine in the list for single-dose subsidy to the elderly in Japan. PLoS ONE. 2015;10(10): e0139140.

Article  PubMed  PubMed Central  Google Scholar 

Johnstone J, Marrie TJ, Eurich DT, Majumdar SR. Effect of pneumococcal vaccination in hospitalized adults with community-acquired pneumonia. Arch Intern Med. 2007;167(18):1938–43.

Article  PubMed  Google Scholar 

Örtqvist Å, Hedlund J, Burman L-Å, Elbel E, Höfer M, Leinonen M, et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Lancet. 1998;351(9100):399–403.

Article  PubMed  Google Scholar 

Sisk JE, Whang W, Butler JC, Sneller V-P, Whitney CG. Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann Intern Med. 2003;138(12):960–8.

Article  PubMed  Google Scholar 

Smith KJ, Wateska AR, Nowalk MP, Raymund M, Lee BY, Zimmerman RK. Modeling of cost effectiveness of pneumococcal conjugate vaccination strategies in US older adults. Am J Prev Med. 2013;44(4):373–81.

Article  PubMed  PubMed Central  Google Scholar 

Stoecker C, Kim L, Gierke R, Pilishvili T. Incremental cost-effectiveness of 13-valent pneumococcal conjugate vaccine for adults age 50 years and older in the United States. J Gen Intern Med. 2016;31(8):901–8.

Article  PubMed  PubMed Central  Google Scholar 

Stoecker C, Kobayashi M, Matanock A, Cho B-H, Pilishvili T. Cost-effectiveness of continuing pneumococcal conjugate vaccination at age 65 in the context of indirect effects from the childhood immunization program. Vaccine. 2020;38(7):1770–7.

Article  PubMed  Google Scholar 

Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database of Syst Rev. 2013;(1).

Evers SMAA, Ament AJHA, Colombo GL, Konradsen HB, Reinert RR, Sauerland D, et al. Cost-effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: an update for 10 Western European countries. Eur J Clin Microbiol Infect Dis. 2007;26(8):531–40.

Article  CAS